Actively Recruiting
Evaluating Effectiveness and Safety of Glofitamab Based Second-Line Therapy in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective Observational Cohort Study
Led by Hoffmann-La Roche · Updated on 2026-06-03
300
Participants Needed
18
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating how well glofitamab-based therapy works and how safe it is in Chinese adults with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who have already received one line of systemic therapy. This prospective, observational, multicenter cohort study aims to collect real-world information on this cancer treatment. The study is sponsored by Hoffmann-La Roche and focuses on adults starting or recently started on glofitamab therapy. Participants will be enrolled either before they begin glofitamab treatment or within 90 days after starting it. No study interventions are given by investigators; instead, participants receive glofitamab as part of their usual cancer care. The study monitors outcomes related to the treatment over about four years. During the study, researchers will track progression-free survival and other outcomes like response rates, duration of response, overall survival, event-free survival, and time to next treatment. These will be assessed up to approximately four years. Participants will be observed in their real-world treatment settings without additional experimental procedures, providing valuable data on how glofitamab performs and its safety in routine care.
CONDITIONS
Brief Title
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed relapsed or refractory diffuse large B-cell lymphoma after one line of systemic therapy
- Planned or ongoing treatment with glofitamab-based regimen started within 90 days prior to enrollment
- Adult participants aged 18 years or older
You will not qualify if you...
- Participation in or planned participation in any interventional clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 4 years
Participants receive glofitamab as part of their cancer-treatment regimen in a real-world setting. The study does not administer the intervention.
Visits occur as part of routine care; specific visit schedule varies by participant
Duration - Up to approximately 4 years
Participants are observed for effectiveness and safety outcomes related to glofitamab treatment over time.
Visit frequency depends on clinical follow-up during and after treatment
Trial Site Locations
Total: 18 locations
1
Cancer Hospital Chinese Academy of Medical Sciences.
Langfang, Hebei, China, 065001
Actively Recruiting
2
Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center
Tianjin, Tianjin Municipality, China, 301636
Actively Recruiting
3
Peking University People's Hospital
Beijing, China, 100044
Actively Recruiting
4
Peking University Third Hospital
Beijing, China, 100191
Actively Recruiting
5
The First Bethune Hospital of Jilin University
Changchun, China
Actively Recruiting
6
West China Hospital of Sichuan University
Chengdu, China, 610041
Actively Recruiting
7
Guangdong Provincial People's Hospital
Guangzhou, China, 510080
Actively Recruiting
8
Harbin Medical University Cancer Hospital
Harbin, China, 150081
Actively Recruiting
9
Shandong Cancer Hospital
Jinan, China, 250117
Actively Recruiting
10
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China, 200025
Actively Recruiting
11
Tianjin Cancer Hospital
Tianjin, China, 300060
Actively Recruiting
12
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China, 325035
Actively Recruiting
13
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
Wuhan, China, 430022
Actively Recruiting
14
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, China, 430030
Actively Recruiting
15
The First Affiliated Hospital of Xian Jiao Tong University
Xi'an, China, 710061
Actively Recruiting
16
Yantai Yu Huangding Hospital
Yantai, China, 264099
Actively Recruiting
17
Henan Cancer Hospital
Zhengzhou, China, 450008
Actively Recruiting
18
Queen Mary Hospital
Hong Kong, Hong Kong
Actively Recruiting
Research Team
R
Reference Study ID Number: ML45172 https://forpatients.roche.com/
F
Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here